1. Home
  2. PSTX
  3. PSTX News

Latest Poseida Therapeutics Inc. (PSTX) News on December 22, 2024

Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
PSTX

Zacks

9 days ago

Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?

PSTX

MT Newswires

11 days ago

Poseida Therapeutics Insider Sold Shares Worth $283,866, According to a Recent SEC Filing

PSTX

MT Newswires

13 days ago

Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
PSTX

PR Newswire

13 days ago

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors
PSTX

Barrons.com

16 days ago

PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors

PSTX

MT Newswires

20 days ago

Piper Sandler Downgrades Poseida Therapeutics to Neutral, $10 Price Target

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
PSTX

Zacks

20 days ago

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
PSTX

Zacks

23 days ago

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
PSTX

Zacks

24 days ago

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
PSTX

Zacks

25 days ago

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
PSTX

Zacks

25 days ago

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?

Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
PSTX

TipRanks

25 days ago

Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Why This Gene-Therapy Company’s Stock Is Rising 228%
PSTX

Barrons.com

a month ago

Why This Gene-Therapy Company’s Stock Is Rising 228%

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
PSTX

Zacks

a month ago

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
PSTX

Benzinga

a month ago

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

PSTX

MT Newswires

a month ago

Sector Update: Health Care

PSTX

MT Newswires

a month ago

Top Premarket Gainers

PSTX

MT Newswires

a month ago

Cantor Fitzgerald Downgrades Poseida Therapeutics to Neutral From Overweight

PSTX

MT Newswires

a month ago

BTIG Downgrades Poseida Therapeutics to Neutral

Roche to acquire Poseida Therapeutics for $1.5bn
PSTX

Pharmaceutical Technology

a month ago

Roche to acquire Poseida Therapeutics for $1.5bn

PSTX

MT Newswires

a month ago

Poseida Therapeutics to Be Acquired by Roche Holdings in $1.5 Billion Deal

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
PSTX

The Wall Street Journal

a month ago

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion

Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
PSTX

Reuters

a month ago

Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
PSTX

PR Newswire

a month ago

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
PSTX

PR Newswire

a month ago

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know
PSTX

Zacks

a month ago

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know

Poseida Therapeutics to Present at Two Upcoming Investor Conferences
PSTX

PR Newswire

a month ago

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations
PSTX

Simply Wall St.

a month ago

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
PSTX

Zacks

a month ago

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
PSTX

PR Newswire

a month ago

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
PSTX

PR Newswire

2 months ago

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Organogenesis Holdings And 2 Other US Penny Stocks To Watch
PSTX

Simply Wall St.

2 months ago

Organogenesis Holdings And 2 Other US Penny Stocks To Watch

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
PSTX

PR Newswire

2 months ago

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

PSTX

MT Newswires

2 months ago

Poseida Nominates New CAR-T Development Candidate, Triggering $15 Million Milestone Payment

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
PSTX

PR Newswire

2 months ago

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

MaxCyte Appoints Cynthia Collins to its Board of Directors
PSTX

GlobeNewswire

2 months ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
PSTX

PR Newswire

3 months ago

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

PSTX

MT Newswires

3 months ago

Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
PSTX

PR Newswire

3 months ago

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1
PSTX

Pharmaceutical Technology

3 months ago

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

PSTX

MT Newswires

3 months ago

Poseida Gets Regenerative Medicine Advanced Therapy Designation for Myeloma Treatment; Shares Rise

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
PSTX

PR Newswire

3 months ago

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
PSTX

PR Newswire

4 months ago

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
PSTX

PR Newswire

4 months ago

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics to Present at Upcoming Investor Conferences
PSTX

PR Newswire

4 months ago

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations
PSTX

Simply Wall St.

4 months ago

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
PSTX

Zacks

5 months ago

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
PSTX

PR Newswire

5 months ago

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains
PSTX

Simply Wall St.

5 months ago

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
PSTX

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
PSTX

PR Newswire

6 months ago

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

BigBear.ai Stock: Buy, Sell, or Hold?
PSTX

Motley Fool

6 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'
PSTX

AFP

6 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?
PSTX

Motley Fool

6 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
PSTX

GuruFocus.com

6 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
PSTX

GuruFocus.com

6 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)
PSTX

Simply Wall St.

6 months ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)
PSTX

Simply Wall St.

6 months ago

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)

VanEck Semiconductor ETF Is Riskier Than You Think
PSTX

Motley Fool

6 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
PSTX

PR Newswire

7 months ago

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

PSTX

MT Newswires

7 months ago

Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
PSTX

PR Newswire

7 months ago

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
PSTX

PR Newswire

7 months ago

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
PSTX

Simply Wall St.

8 months ago

Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher

Xyphos and Poseida to develop allogeneic cell therapies for cancer
PSTX

Pharmaceutical Technology

8 months ago

Xyphos and Poseida to develop allogeneic cell therapies for cancer

PSTX

MT Newswires

8 months ago

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
PSTX

PR Newswire

8 months ago

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
PSTX

PR Newswire

8 months ago

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
PSTX

BioPharma Dive

8 months ago

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
PSTX

PR Newswire

8 months ago

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
PSTX

PR Newswire

8 months ago

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
PSTX

PR Newswire

8 months ago

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PSTX

PR Newswire

9 months ago

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
PSTX

PR Newswire

9 months ago

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PSTX

PR Newswire

9 months ago

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
PSTX

PR Newswire

9 months ago

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results
PSTX

Simply Wall St.

9 months ago

US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results

Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations
PSTX

Simply Wall St.

9 months ago

Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations

PSTX

GuruFocus.com

10 months ago

Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
PSTX

Zacks

10 months ago

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
PSTX

PR Newswire

10 months ago

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PSTX

PR Newswire

10 months ago

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Institutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)
PSTX

Simply Wall St.

10 months ago

Institutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Investors in GoPro (NASDAQ:GPRO) have unfortunately lost 65% over the last three years
PSTX

Simply Wall St.

a year ago

Investors in GoPro (NASDAQ:GPRO) have unfortunately lost 65% over the last three years

As investors pile into psychedelics, idealism gives way to pharma economics
PSTX

Associated Press Finance

a year ago

As investors pile into psychedelics, idealism gives way to pharma economics

Central Pacific Financial Corp. (NYSE:CPF) Q4 2023 Earnings Call Transcript
PSTX

Insider Monkey

a year ago

Central Pacific Financial Corp. (NYSE:CPF) Q4 2023 Earnings Call Transcript

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PSTX

PR Newswire

a year ago

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

The Logistics Play Set to Transform the Permian Basin
PSTX

Oilprice.com

a year ago

The Logistics Play Set to Transform the Permian Basin

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024
PSTX

GlobeNewswire

a year ago

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024

Is Weakness In Daktronics, Inc. (NASDAQ:DAKT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
PSTX

Simply Wall St.

a year ago

Is Weakness In Daktronics, Inc. (NASDAQ:DAKT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
PSTX

Zacks

a year ago

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Chuck Royce Reduces Stake in NVE Corp
PSTX

GuruFocus.com

a year ago

Chuck Royce Reduces Stake in NVE Corp

NVE Corp's Dividend Analysis
PSTX

GuruFocus.com

a year ago

NVE Corp's Dividend Analysis

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)
PSTX

Insider Monkey

a year ago

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)
PSTX

StockStory

a year ago

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)

2 Network Software Stocks to Buy From a Prospering Industry
PSTX

Zacks

a year ago

2 Network Software Stocks to Buy From a Prospering Industry

Metals Acquisition Limited Provides Operational Update
PSTX

Business Wire

a year ago

Metals Acquisition Limited Provides Operational Update

Potbelly (PBPB) Boosts Offerings With Revamped Loyalty Program
PSTX

Zacks

a year ago

Potbelly (PBPB) Boosts Offerings With Revamped Loyalty Program

8x8, Inc. Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call
PSTX

Business Wire

a year ago

8x8, Inc. Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call

DSW Parent Designer Brands Taps Andrea O’Donnell as Brands President
PSTX

WWD

a year ago

DSW Parent Designer Brands Taps Andrea O’Donnell as Brands President

Share on Social Networks: